AXL and Miyoshi myopathy: In vivo targeting of AXL with BMS-777607 or cabozantinib significantly reduced the number of dormant MM cells and increased proliferating MM cells, indicating that AXL inhibition releases MM cells from dormancy and sensitizes them to chemotherapy.